Roland Lawson

Roland Lawson

Auto-generated profile, based on publicly available information

Roland Lawson

University of Limoges, Inserm U1248, Pharmacology & Transplantation, Limoges, France

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
LMLuc Maroteaux
Luc Maroteaux
EAEstelle Ayme-Dietrich
Estelle Ayme-Dietrich
GAGaëlle Aubertin-Kirch
Gaëlle Aubertin-Kirch
SBSophie Banas
Sophie Banas
EQEmily Quentin
Emily Quentin
LMLaurent Monassier
Laurent Monassier

7 January 2016 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
HOHajer El Oussini
Hajer El Oussini
HBHanna Bayer
Hanna Bayer
JSJelena Scekic-Zahirovic
Jelena Scekic-Zahirovic
PVPauline Vercruysse
Pauline Vercruysse
JSJérôme Sinniger
Jérôme Sinniger
LDLuc Dupuis
Luc Dupuis

15 October 2017 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
EAEstelle Ayme-Dietrich
Estelle Ayme-Dietrich
RLRoland Lawson
Roland Lawson
FCFrancine Côté
Francine Côté
CTClaudia de Tapia
Claudia de Tapia
SSSylvia Da Silva
Sylvia Da Silva
LMLaurent Monassier
Laurent Monassier

1 February 2019 in Pharmacological Research
Verified
Journal Article
Closed access
EAEstelle Ayme-Dietrich
Estelle Ayme-Dietrich
RLRoland Lawson
Roland Lawson
SDSylvia Da-Silva
Sylvia Da-Silva
JMJean Philippe Mazzucotelli
Jean Philippe Mazzucotelli
LMLaurent Monassier
Laurent Monassier

1 November 2015 in Journal Of Hypertension
Verified
Journal Article
Closed access
EAEstelle Ayme-Dietrich
Estelle Ayme-Dietrich
HMHalim Marzak
Halim Marzak
RLRoland Lawson
Roland Lawson
WMWalid Mokni
Walid Mokni
OWOlivia Wendling
Olivia Wendling
LMLaurent Monassier
Laurent Monassier
Objective: Left-ventricular hypertrophy and interstitial fibrosis are the main pathophysiological factors of heart failure with preserved ejection fraction. Blockade of the serotonin 5-HT2B receptor (5-HT2BR) has been shown to reduce cardiac hypertrophy, oxidative stress, and extracellular cell matrix activation. In this study, we evaluated the effects of the 5-HT2BR blockade, on hemodynamic and cardiac remodeling, in spontaneously hypertensive rats (SHRs) that display a diastolic dysfunction with preserved ejection fraction. Method: Thirty-seven-week-old SHRs were randomized in four groups receiving either saline, the selective 5-HT2BR antagonist RS-127445 (1 mg/kg per day), a calcium channel blocker nicardipine (6 mg/kg per day), or RS-127445 + nicardipine. During the 14 weeks of treatment period, cardiac function and blood pressure were monitored by echocardiography and tail-cuff. Finally, electrocardiograms and invasive hemodynamics were obtained before blood collection. Heart was analyzed for morphology and mRNA expression. A complementary study evaluated the cardiac and vascular effects of serotonin on wild-type and mice knockout for the 5-HT2BR (Htr2B−/−) and/or the 5-HT2AR (Htr2A−/−). Results: Despite the left ventricular 5-HT2BR overexpression, 5-HT2BR blockade by RS-127445 did not affect left ventricular hypertrophy and fibrosis in SHRs. This antagonist did not improve diastolic dysfunction, neither alone nor in combination with nicardipine, although it induced plasma brain natriuretic peptide decrease. Moreover, RS-127445 amplified subendocardial fibrosis and favored left ventricular dilatation. Finally, a subendocardial left ventricular fibrosis was induced by chronic serotonin in wild-type mice, which was increased in Htr2B−/− animals, but prevented in Htr2A−/− and Htr2A/2B−/− mice, and could be explained by a contribution of the endothelial 5-HT2BRs to coronary vasodilatation. Conclusion: This work is the first to identify a cardioprotective function of the 5-HT2BR in an integrated model of diastolic dysfunction with preserved ejection fraction.

28 October 2021 in BMC Pharmacology and Toxicology
Verified
Journal Article
Open access
PDF file
MJManon Jardou
Manon Jardou
QPQuentin Provost
Quentin Provost
CBClarisse Brossier
Clarisse Brossier
EPEmilie Pinault
Emilie Pinault
FSFrançois-Ludovic Sauvage
François-Ludovic Sauvage
RLRoland Lawson
Roland Lawson
Background: Mycophenolic acid (MPA) is the most widely used immunosuppressive drug in transplantation and for autoimmune diseases. Unfortunately, more than 30% of patients experience a typical gastrointestinal adverse effect also referred to as mycophenolate-induced enteropathy. Due to its antibacterial, antifungal, and antiviral properties, MPA exposure is associated with intestinal dysbiosis characterized by a decrease in density and diversity of the microbiome regarding the main bacterial phyla (Firmicutes and Bacteroidetes). These bacterial phyla are known for their metabolic role in maintaining the homeostasis of the digestive tract, particularly through the production of short-chain fatty acids (SCFA) that could contribute to the pathophysiology of mycophenolate-induced enteropathy. Our study aimed at deciphering short-chain fatty acids (SCFA) profile alterations associated with gastrointestinal toxicity of MPA at the digestive and systemic levels in a mouse model.Methods: Ten-week old C57BL/6 (SOPF) mice were randomly assigned in 2 groups of 9 subjects: control, and mycophenolate mofetil (MMF, 900 mg/kg/day). All mice were daily treated by oral gavage for 7 days. Individual faecal pellets were collected at days 0, 4 and 8 as well as plasma at day 8 for SCFA profiling. Additionally, after the sacrifice on day 8, the caecum was weighted, and colon length was measured. The proximal colon was cut for histological analysis.Results: MMF treatment induced around 10% weight loss at the end of the protocol associated with a significant decrease in caecum weight and a slight reduction in colon length. Histological analysis showed significant architectural changes in colon epithelium. Moreover, we observed an overall decrease in SCFA concentrations in faecal samples, especially regarding acetate (at day 8, control 1040.6 ± 278.161 μM versus MMF 384.7 ± 80.5 μM,p< 0.01) and propionate (at day 8, control 185.94 ± 51.96 μM versus MMF 44.07 ± 14.66 μM,p< 0.001), and in plasma samples for butyrate (at day 8, control 0.91 ± 0.1 μM versus MMF 0.46 ± 0.1 μM,p <0.01).Conclusions: These results are consistent with functional impairment of the gut microbiome linked with digestive or systemic defects during MMF treatment.